Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...
Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including ...
Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...
The impact of digital transformation, increased regulation, rising costs, bouncing tariffs and volatile geopolitics are just some of the big issues keeping Australian business leaders up at night.
MedPage Today on MSN
Trop2 Drug Extends Survival in EGFR-Mutated Lung Cancer
The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback